How have mathematical models contributed to understanding

the transmission and control of SARS-CoV-2 in healthcare

settings? A systematic search and review

- 5 Authors: David R M Smith*^{1,2,3}, Sophie Chervet*^{1,2,4}, Théo Pinettes^{3,5}, George Shirreff^{1,2,3},
- 6 Sofía Jijón^{3,5}, Ajmal Oodally^{1,2,3}, Kévin Jean^{3,5}, Lulla Opatowski**^{1,2}, Solen Kernéis**^{4,6}, Laura
- 7 Temime**^{3,5}

1

2

4

10

11

- 8 *Contributed equally
- 9 **Contributed equally

Institutional affiliations:

- 12 ¹ Institut Pasteur, Epidemiology and Modelling of Antibiotic Evasion (EMAE), Paris, France
- 13 ² INSERM, Centre de recherche en épidémiologie et santé des populations (CESP), UMR
- 14 1018, "Anti-infective Evasion and Pharmacoepidemiology" team, UVSQ, Université Paris-
- 15 Saclay, Montigny-Le-Bretonneux, France
- 16 ³ Conservatoire national des Arts et Métiers, Laboratoire Modélisation, épidémiologie et
- 17 surveillance des risques sanitaires (MESuRS), Paris, France
- 18 INSERM, Infection, Antimicrobials, Modelling, Evolution (IAME), UMR 1137, Université
- 19 Paris-Cité, Paris, France
- ⁵ Conservatoire national des Arts et Métiers, Institut Pasteur, Unité Pasteur-Cnam sur les
- 21 Risques Infectieux et émergents (PACRI), Paris, France
- ⁶ AP-HP, Hôpital Bichat, Equipe de Prévention du Risque Infectieux (EPRI), Paris, France

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

Abstract **Background:** Since the onset of the COVID-19 pandemic, mathematical models have been widely used to inform public health recommendations regarding COVID-19 control in healthcare settings. **Objectives:** To systematically review SARS-CoV-2 transmission models in healthcare settings, and summarise their contributions to understanding nosocomial COVID-19. **Methods:** Systematic search and review. **Data sources:** Published articles indexed in PubMed. Study eligibility criteria: Modelling studies describing dynamic inter-individual transmission of SARS-CoV-2 in healthcare settings, published by mid-February 2022. Participants and interventions: Any population and intervention described by included models. **Assessment of risk of bias:** Not appropriate for modelling studies. **Methods of data synthesis:** Structured narrative review. Results: Models have mostly focused on acute care and long-term care facilities in highincome countries. Models have quantified outbreak risk across different types of individuals and facilities, showing great variation across settings and pandemic periods. Regarding surveillance, routine testing – rather than symptom-based testing – was highlighted as essential for COVID-19 prevention due to high rates of silent transmission. Surveillance impacts were found to depend critically on testing frequency, diagnostic sensitivity, and turnaround time. Healthcare re-organization was also found to have large epidemiological impacts: beyond obvious benefits of isolating cases and limiting inter-individual contact, more complex strategies such as staggered staff scheduling and immune-based cohorting reduced infection risk. Finally, vaccination impact, while highly effective for limiting COVID-19 burden, varied substantially depending on assumed mechanistic impacts on infection

acquisition, symptom onset and transmission. Studies were inconsistent regarding which individuals to prioritize for interventions, probably due to the high diversity of settings and populations investigated.

Conclusions: Modelling results form an extensive evidence base that may inform control strategies for future waves of SARS-CoV-2 and other viral respiratory pathogens. We propose new avenues for future models of healthcare-associated outbreaks, with the aim of enhancing their efficiency and contributions to decision-making.

Introduction

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

SARS-CoV-2 transmission in healthcare settings has contributed significantly to the global health-economic burden of COVID-19. Healthcare settings are particularly vulnerable to COVID-19, due to dense concentrations of frail patients, high frequencies of at-risk medical procedures, and high rates of inter-individual contact. Both patients and healthcare workers (HCWs) have been at high risk of SARS-CoV-2 infection throughout the pandemic, resulting in major nosocomial outbreaks worldwide [1,2]. In England, for instance, an estimated 20% of patients hospitalized with COVID-19 before August 2020 acquired their infection in hospital [3], while 95,000-167,000 patients became infected during their hospital stay between June 2020 and March 2021 [4]. Further, HCWs have experienced an estimated 1.6to 3.4-fold higher risk of infection relative to the general population [5,6]. Long-term care facilities (LTCFs) have been most severely impacted, with one- to two-thirds of COVIDrelated deaths in Europe by May 2020 estimated to have occurred among LTCF residents [7]. Healthcare facilities have undergone extensive organizational changes to combat SARS-CoV-2 transmission, particularly during local surges in COVID-19 cases. Many facilities have adopted non-pharmaceutical infection prevention and control (IPC) measures, including social distancing, reinforced contact precautions and hand hygiene procedures, use of personal protective equipment (PPE), banning of visitors, and systematic test-trace-isolate protocols. HCWs and residents of LTCFs have also been among the first populations targeted for vaccination. However, despite these interventions, nosocomial COVID-19 risk has not been eliminated, as evidenced by ongoing outbreaks in healthcare facilities worldwide. A key barrier to effective COVID-19 prevention in healthcare settings is imperfect understanding of transmission routes among patients and HCWs, and of the relative impacts of different control strategies, which depend on setting-specific organizational and demographic characteristics, immunological histories of the specific population concerned, and virological properties of locally circulating variants.

Throughout the pandemic, mathematical models (Box 1) have proven useful both to better understand the epidemiological processes underlying SARS-CoV-2 outbreaks and to support public health decision-making. Modelling studies focusing on nosocomial risk in particular, although less publicized than those focusing on community risk, have addressed a broad range of epidemiological questions [8] and aided public health decision-making [9]. However, epidemiological insights and public health recommendations from nosocomial SARS-CoV-2 models have not previously been reviewed or synthesized systematically. Here, we systematically search and review mathematical models developed to investigate SARS-CoV-2 transmission dynamics and control strategies in healthcare settings over the critical phase of the pandemic, present their main contributions, synthesize their conclusions, and discuss their limits.

<u>Methods</u>

We conducted a systematic search and review of mathematical/mechanistic models of inter-

individual SARS-CoV-2 transmission within healthcare settings published up to February 14,

2022. Details on the search, inclusion and exclusion criteria, screening process and data

extraction are provided in the Supplementary File, and results are reported according to the

PRISMA guidelines [10] (see Supplementary File).

Results

Model characteristics

Overall, our search identified 1,431 studies, of which 59 were included after title, abstract

and full-text screening (Suppl. Fig. S1 and Suppl. Table). Most (43/59) were posted in a

publicly accessible pre-print server, with a median delay of 8 months (range: 1 to 24 months)

between initial preprint posting and publication.

The majority of models were stochastic (85%; 50/59), and about half were agent-based or

network models (53%; 31/59). At early stages of the pandemic, when testing resources were

highly limited, most studies focused on surveillance and healthcare organization (Fig. 1A).

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

By comparison, impacts of PPE have been assessed less frequently, and vaccination strategies only began to be explored towards the end of 2020, as the first vaccines became available. While models were mostly developed by teams from the USA, the UK, and other European countries, these models explored locations representing a wider range of countries worldwide (Fig. 1B). Acute care facilities and long-term care facilities were the main types of healthcare facilities considered, although this varied depending on the country of study (Fig. 1C) and the subject addressed (Fig. 1D). Insights on SARS-CoV-2 acquisition routes and transmission risk Few studies have attempted to estimate the reproduction number of SARS-CoV-2 in healthcare settings, despite evidence that nosocomial and community risk may differ widely [11]. Estimates of nosocomial R₀ range from 0.45 (0.36-0.56) in English acute care hospitals using a relatively simple approach [12] to 8.72 (5.14-16.32) in a French LTCF using a stochastic dynamic model accounting for imperfect surveillance [13]. Interestingly, in the latter study, R_0 was estimated to drop to 1.33 (0.68-2.04) after introduction of control measures. Several models have quantified the relative burden of SARS-CoV-2 infection and transmission among patients and HCWs over the course of the pandemic. HCWs were identified as being at high risk of occupational exposure to infection, either from colleagues or patients [14–16]. During the first wave in early 2020, they have been estimated to be the most important source of onward nosocomial transmission, both to patients and other HCWs [17,18]. However, other studies found that patient infection could result primarily from transmission from other patients [4,16,18]. Insights on SARS-CoV-2 infection control

Evaluating and optimizing surveillance strategies

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

Models have been widely used to assess and compare the epidemiological impacts of SARS-CoV-2 testing strategies. Because SARS-CoV-2 spreads extensively through presymptomatic and asymptomatic transmission [19,20], the identification of non-symptomatic infections is a key component of nosocomial IPC. Several studies have highlighted difficulty controlling outbreaks when targeting only symptomatic individuals for testing [21-28]. Limited impact of only testing patients upon their admission has also been identified, suggesting that more thorough screening methods are required to limit SARS-CoV-2 introductions from the community, visitors, HCWs or ancillary staff [24,27,29,30]. Many studies have evaluated the impact of routine testing of non-symptomatic individuals. The most universal finding is that more frequent testing leads to greater reductions in nosocomial transmission [12,14,21,23,24,30-40]. Similarly, increasing daily testing capacity has been found to limit nosocomial transmission [27,41]. In the context of limited test availability early in the pandemic, effective strategies identified for optimizing nosocomial outbreak detection include pooling samples via group testing [27] and distributing tests over several batches instead of using them all at once [42]. Modelling results are less consistent concerning which subpopulations to target for routine non-symptomatic testing. Many conclude that targeting HCWs is most effective [12,25,32,43], while others suggest targeting facility patients or residents [22,27,39]. Divergence owes to underlying modelling assumptions on how patients and HCWs differ, regarding their infectiousness, susceptibility to infection, contact behaviour, and degree of interaction with visitors and other individuals in the community. For instance, testing staff proved more effective in a model of English care homes where the main source of SARS-CoV-2 introductions was staff members infected in the community [25]. Conversely, testing patients was more effective in models of a French rehabilitation hospital in which high rates of contact among ambulatory patients translated to high rates of patient-to-patient transmission [27,39]. In nursing homes, patient testing likely becomes increasingly important when visitors or other interactions with the community are permitted [33].

Lastly, in addition to testing frequency, studies have quantified the critical impact of the sensitivity and turnaround time of the test being used [24,28,30,32,33,37,38,44–47]. Several studies have identified that gains in turnaround time tend to outweigh gains in test sensitivity, explaining why rapid diagnostic tests (e.g. Ag-RDT) may be more effective than laboratory-based tests (e.g. RT-PCR) for routine non-symptomatic testing [23,25,32,39]. Conversely, if same-day test results are achievable, or if individuals effectively isolate while awaiting test results, more sensitive laboratory tests likely outperform rapid tests [33,34,44].

Evaluating impacts of personal protective equipment (PPE)

Several studies have found that, when available, PPE use is highly effective for reducing infection risk among both HCWs and patients. Although predicted reductions in infection risk naturally depend on assumptions underlying PPE's impact on viral transmissibility, which vary considerably across studies and for which data are sorely lacking, several studies suggest that widespread PPE use remains a key SARS-CoV-2 prevention strategy, even when conferring comparatively low levels of protection [15,29,37,48–50]. By preventing infection, PPE use has also been shown to reduce HCW workplace absence [37] and workday loss [22]. Very few studies have tackled the question of who should be given priority to PPE access when in limited supply, although PPE has been shown to be particularly effective when accessible to all HCWs [48].

Regarding different types of PPE that may be used, Hüttel et al. [15] found hand sanitizer to

be an effective means of reducing risk as a supplement to other strategies. Regarding timing, earlier introduction of PPE was found to allow a much more efficient response [22] and to enable prevention of large outbreaks [25]. However, further analyses suggest that the level of protection PPE confers can be occasionally overwhelmed in the context of large numbers of infected people in a room [51]. Finally, waning PPE adherence due to pandemic fatique could significantly impact the efficacy of PPE-based interventions [52].

Evaluating and optimizing healthcare organization

Many modelling studies have assessed the epidemiological impacts of healthcare facilities adapting their structures of care and workplace organization. Larger facilities have been found to be at greater risk of nosocomial SARS-CoV-2 outbreaks [43], and splitting facilities into smaller independent units has been shown to reduce the total number of infected individuals [36,48], except when transmissibility is high [53]. Forbidding visitors was identified as not having a significant effect on outbreak probability [25], except when infection prevalence among visitors' contacts in the community is higher than that of HCW community contacts [54]. Models have highlighted that rapid isolation of positive cases is an effective strategy for infection prevention [36,55,56]. Interestingly, models suggest that intermixing recovered individuals with potentially susceptible individuals could reduce outbreak size [32], and that sufficient spacing between patient beds is needed to limit transmission risk [36]. Results are less consistent regarding isolation upon admission. Models have highlighted the efficacy of isolating all newly admitted patients for a given duration [29] or while awaiting test results [12]. Conversely, others report no additional benefit of front-door screening or guarantine upon admission when other strategies are already in place [43,55]. Regarding staff organization, models have demonstrated benefits of cancelling HCW gatherings [57,58] and of forcing shorter and fewer patient-HCW interactions [51,58], although surprisingly this latter result was not confirmed by others [22]. Reducing betweenward staff sharing also seems to reduce both the number of wards with infected individuals [55] and the global reproduction number [37]. More complex staffing strategies have also shown potential benefits, like splitting staff into two teams that do not interact [59,60], synchronizing rather than staggering staff rotations [61], or immunity-based staffing [32,35], e.g. assigning recovered staff to infected patients [35]. Finally, admitting all COVID-19 patients to specialized quarantine hospitals in which HCWs continuously resided for 1-to-2 week-long shifts did not necessarily increase occupational HCW risk [62].

Evaluating vaccination strategies

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

All models exploring vaccination found that it could help reduce COVID-19 morbidity and mortality, especially in LTCFs [23,28,31,33,52,63-67]. However, some studies also noted that vaccination benefits could be hindered by high levels of community SARS-CoV-2 circulation [31,65] or by reduced adherence to contact precautions within facilities concomitant with vaccine rollout, for instance due to pandemic fatigue or risk compensation [52]. A major focus of these models has been evaluation of which groups of individuals to target or prioritize for vaccination in a context of limited vaccine availability, yielding sometimes inconsistent results. Some found that LTCF residents should be prioritized over staff, especially in LTCFs with low adherence to IPC measures [33,52]. Conversely, staff vaccination was shown to be particularly effective for decreasing the overall attack rate, especially in the absence of a testing protocol [64]. Targeting staff for vaccination may also be preferable when the risk of virus importation from the community is high [31]. Finally, it has been shown that vaccine rollout should first target staff members most exposed to potential COVID-19 patients (e.g. staff from emergency departments) [63]. It should be noted that the conclusions reached by these models depend strongly on modelling assumptions underlying vaccine action. Across models, assumed mechanisms related to vaccination effectiveness included one or several of the following: a reduction in acquisition risk, a reduction in symptom risk, and a reduction in the infectiousness of infected vaccinated individuals. For instance, it was shown that if a vaccine only reduces symptom risk, then increasing vaccination among nursing home staff leads to an increase in the proportion of asymptomatic infections among staff, which subsequently leads to increased infection risk for residents [23]. Additionally, no model considered vaccine impact over the long-term, which is particularly relevant in the context of waning immunity and the emergence of novel variants with vaccine-escape properties.

Discussion

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

Mathematical models have become ubiquitous tools to help understand the dynamics of infectious disease outbreaks and to support public health decision-making. Here, we have reviewed how models have helped to inform COVID-19 risk management in healthcare settings, in particular by providing a better understanding of nosocomial transmission dynamics and control strategy effectiveness. The generation of in silico evidence to inform infection control strategies has been the leading motivation for nosocomial SARS-CoV-2 transmission modelling. Although real-world evidence collected during randomized controlled trials is the gold-standard, such data are extremely difficult to generate in the context of a rapidly evolving epidemic. Beyond the obvious costs and time involved, great heterogeneity in population characteristics and exposure risk across different healthcare settings means that a large number of centres must be enrolled to achieve sufficient cluster randomisation. Several high-impact randomized controlled trials have nonetheless been successfully conducted in healthcare settings despite these challenges, in particular to evaluate COVID-19 vaccines, therapies and pre- or post-exposure prophylactic agents [68–71]. However, trials evaluating impacts of common IPC interventions, including surveillance testing, PPE and healthcare reorganization, are scarce [72,73]. In this context, mathematical modelling approaches have been particularly helpful to investigate critical IPC questions in (near) real-time, since they allow for the simulation of diverse scenarios at relatively high speed and low cost, while accounting for all available knowledge and uncertainty at a given place and time. Model-based evaluations also allow for levels of granularity in intervention arms that may be infeasible in real trial designs. Our review highlights the range of modelling studies published before the end of 2020, at a time when the scientific and medical communities were in particularly great need of evidence to inform optimal allocation of limited infection prevention resources, including RT-PCR tests, face masks and, later, vaccines.

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

However, two common means of SARS-CoV-2 transmission prevention with important implications for the field have been notably under-addressed. First, modelling studies on the relative impact of different types of face masks (e.g. surgical masks, N95 respirators) are scarce [74], tied to a lack of precise data on how they impact viral transmissibility, as well as their potential indirect roles as transmission vectors. Second, although ubiquitous in practice at various stages of the pandemic, explicit social distancing interventions have rarely been assessed [22,39]. This is probably because accurate modelling of social distancing requires fine-scaled simulation of inter-individual contact networks, typically using an agent-based approach, which is beyond the scope of most models. When faced with both epistemic uncertainty and a need for relative computational simplicity, modelers may be reluctant to include and formalize specific interventions that require arbitrary, highly sophisticated and/or potentially wrongheaded assumptions about their mechanistic impacts on SARS-CoV-2 transmission. Instead, a common modelling strategy has been to include generic nonpharmaceutical interventions that simply reduce the viral transmission rate, and which are assumed to represent any combination of basic infection prevention interventions, including face masks, gloves, gowns, face shields, hand hygiene or social distancing. Relative to the evaluation of infection control strategies, modelling studies have more rarely focused on the estimation of epidemiological parameters using statistical inference. In particular, in the event of the sudden emergence of a novel infectious disease, R_0 estimation is essential for epidemic forecasting and emergency response planning, and relies largely on mathematical modelling approaches. Although estimates of R_0 quickly became available for SARS-CoV-2 across various community settings in early 2020, [75], estimates specific to healthcare settings remain scarce. Yet there is a great need for robust estimates across diverse settings, as underlying levels of epidemic risk vary substantially across facilities due to their intrinsic heterogeneity (e.g. types of care provided, population sizes, contact behaviour of these populations). For instance, assuming R_0 =3.5 in the community, Temime et al. [11] estimated that nosocomial R₀ could range from 0.7 to 11.7, depending on the type

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

of ward and the density of contacts among and between patients and HCWs. This heterogeneity in nosocomial R_0 is consistent with the range of estimates derived from models described in this review [12,13], and has critical implications, informing which facilities and populations are most at risk for explosive outbreaks and thus most in need of urgent infection control measures. This lack of evidence likely stems from both data limitations and remaining uncertainty about the relative importance of precise paths of transmission (e.g. through direct person-to-person contact; transient viral carriage on hands, garments or shared medical devices; stagnant air in poorly ventilated spaces). Particularly early in the pandemic, nosocomial COVID-19 data came primarily from contexts of emergency outbreak management rather than routine data collection through stable surveillance systems. For future waves of SARS-CoV-2 and other infectious diseases, the estimation of epidemiological parameters may be made easier by harnessing large databases that systematically gather patient and HCW tests results, administrative data and healthcare exposures across diverse healthcare facilities over time. Researchers have faced significant challenges when developing SARS-CoV-2 transmission models. First, data limitations, particularly early in the pandemic, forced many modelers to make assumptions that oversimplify healthcare facility structure, population behaviour and SARS-CoV-2 transmission dynamics, limiting the applicability of some results to real-world settings. Second, the shifting epidemiological landscape - characterized not only by the rapid spread of SARS-CoV-2, but also rapid change in population behaviours, sudden resource shortages, consecutive changes in public health recommendations, rapid approval of novel diagnostics, therapies and vaccines, and the successive emergence of distinct variants of concern - required researchers to continually adapt their models in order to remain useful, with relevant data required to parameterize these updates often lagging behind. Greater interdisciplinarity will be required to maximize the utility of mathematical modelling in the future. More direct lines of contact between modelers, hospital infection control teams,

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

clinicians and decision-makers should guide modelers in their research. First, this may help to steer studies towards the questions that are most clinically relevant, as informed by the needs and issues faced in real clinical settings. Second, this may help modelers to evaluate strategies that are feasible in practice, considering logistical constraints such as workforce or equipment availability and hospital structure. Third, these discussions may inspire modelers to account for outcomes beyond transmission risk and infection burden, such as costeffectiveness or mental health. Indeed, interventions such as visitor restrictions or staff reorganization can have a great impact on the social isolation of patients or workload of HCWs, which is difficult to take into account explicitly in mathematical models. Costeffectiveness is increasingly considered in modelling studies; for instance, several studies have quantified the health-economic efficiency of frequent non-symptomatic testing [12,24,38,39,45]. However, more frequent estimation of health-economic outcomes may increase their usefulness for decision-makers, who must balance the competing priorities of maximizing population health and minimizing monetary cost. Finally, increased communication across disciplines may facilitate more timely sharing of modelling results to those who may benefit from them most, including infection control teams and hospital administrators. The use of social media and the surge in posting of articles on pre-print repositories during the COVID-19 pandemic have helped to facilitate the timely sharing of results, but there remains an onus on academic publishers to ensure a timely peer review process so that modelling results are shared quickly enough to maximize their impact. This review has several limitations. First, we chose to exclude all statistical, mathematical, or computational models not including inter-individual SARS-CoV-2 transmission. Consequently, other types of models such as physical or biomechanical models of airborne transmission were excluded [76–78]. Second, we excluded articles posted on public archives such as arXiv, medrXiv or biorXiv [79], which are not subject to peer review and can be difficult to track. Although we did include some preprints in our review, we were unable to systematically explore these archives. Third, we may have missed articles published in journals not referenced in PubMed (e.g. computer science or mathematical journals). However, since our focus was on epidemiological insights and public health recommendations, we do not believe that this significantly impacted our main findings.

Conclusion

Often developed in the face of great epidemiological uncertainty, mathematical models have come to form a rich evidence base describing how SARS-CoV-2 spreads in healthcare settings and informing which nosocomial COVID-19 control strategies are optimal, in particular with regards to healthcare reorganization and the allocation of limited supplies of PPE, diagnostic testing and vaccines. Into the future, epidemiological models may continue to inform control strategies for outbreaks of SARS-CoV-2 and other viral respiratory pathogens, but increased collaboration should be sought between modelers, hospital infection control teams, clinicians, and public health decision-makers to help maximize their utility.

Conflict of interest

Authors report no conflict of interest.

Funding

This study received funding from the MODCOV project from the Fondation de France (Grant 106059) as part of the alliance framework "Tous unis contre le virus", the Université Paris-Saclay (AAP Covid-19 2020) and the French government through its National Research Agency project SPHINX-17-CE36-0008-01 and the "Investissement d'Avenir" program, Laboratoire d'Excellence "Integrative Biology of Emerging Infectious Diseases" (Grant ANR-10-LABX-62- IBEID). The work was also supported directly by internal resources from the French National Institute for Health and Medical Research (Inserm), Institut Pasteur, le Conservatoire National des Arts et Métiers, and l'Université Versailles Saint-Quentin-en-Yvelines/Université Paris-Saclay.

401

402

403

[8]

Author contributions 372 LO, LT, SK conceived the study, LO and LT acquired the funding. Screening of the articles 373 was performed by DRMS, SC, GS, SJ, KJ, LO and LT. Data extraction and analysis were 374 performed by DRMS, SC, GS, SJ, LO and LT. DRMS, SC and TP rendered figures and 375 statistics. All authors contributed to writing. 376 References 377 [1] Zhou Q, Gao Y, Wang X, Liu R, Du P, Wang X, et al. Nosocomial infections among 378 patients with COVID-19, SARS and MERS: a rapid review and meta-analysis. Ann 379 Transl Med 2020;8:629. https://doi.org/10.21037/atm-20-3324. Leclerc QJ, Fuller NM, Knight LE, CMMID COVID-19 Working Group, Funk S, 380 [2] 381 Knight GM. What settings have been linked to SARS-CoV-2 transmission clusters? 382 Wellcome Open Res 2020;5:83. https://doi.org/10.12688/wellcomeopenres.15889.2. 383 [3] Knight GM, Pham TM, Stimson J, Funk S, Jafari Y, Pople D, et al. The contribution 384 of hospital-acquired infections to the COVID-19 epidemic in England in the first half 385 of 2020. BMC Infect Dis 2022;22:556. https://doi.org/10.1186/s12879-022-07490-4. 386 [4] Cooper B, Evans S, Jafari Y, Pham TM, Lim C, Pritchard M, et al. The burden and 387 dynamics of hospital-acquired SARS-CoV-2 in England. Res Sq 2021. 388 https://doi.org/10.21203/rs.3.rs-1098214/v1. 389 [5] Iversen K, Bundgaard H, Hasselbalch RB, Kristensen JH, Nielsen PB, Pries-Heje M, 390 et al. Risk of COVID-19 in health-care workers in Denmark: an observational cohort 391 study. Lancet Infect Dis 2020;20:1401–8. https://doi.org/10.1016/S1473-392 3099(20)30589-2. 393 [6] Nguyen LH, Drew DA, Graham MS, Joshi AD, Guo C-G, Ma W, et al. Risk of 394 COVID-19 among front-line health-care workers and the general community: a 395 prospective cohort study. Lancet Public Health 2020;5:e475–83. 396 https://doi.org/10.1016/S2468-2667(20)30164-X. 397 [7] ECDC Public Health Emergency Team, Danis K, Fonteneau L, Georges S, Daniau C, 398 Bernard-Stoecklin S, et al. High impact of COVID-19 in long-term care facilities, 399 suggestion for monitoring in the EU/EEA, May 2020. Euro Surveill 2020;25. 400 https://doi.org/10.2807/1560-7917.ES.2020.25.22.2000956.

Zhang W, Liu S, Osgood N, Zhu H, Qian Y, Jia P. Using simulation modelling and

2022. https://doi.org/10.1002/sres.2897.

systems science to help contain COVID-19: A systematic review. Syst Res Behav Sci

404 [9] Opatowski L, Temime L. Contributions of modelling for the control of COVID-19 405 nosocomial transmission. Anaesth Crit Care Pain Med 2022;41:101054. https://doi.org/10.1016/j.accpm.2022.101054. 406 407 [10] Page, McKenzie, Bossuyt, Boutron, Hoffmann, Mulrow CD, et al. The PRISMA 408 2020 statement: an updated guideline for reporting systematic reviews. BMJ 409 2021;372:n71. https://doi.org/10.1136/bmj.n71. 410 [11]Temime L, Gustin M-P, Duval A, Buetti N, Crépey P, Guillemot D, et al. A 411 conceptual discussion about the basic reproduction number of severe acute respiratory 412 syndrome coronavirus 2 in healthcare settings. Clin Infect Dis 2021;72:141–3. 413 https://doi.org/10.1093/cid/ciaa682. 414 [12] Evans S, Agnew E, Vynnycky E, Stimson J, Bhattacharya A, Rooney C, et al. The 415 impact of testing and infection prevention and control strategies on within-hospital 416 transmission dynamics of COVID-19 in English hospitals. Philos Trans R Soc Lond B 417 Biol Sci 2021;376:20200268. https://doi.org/10.1098/rstb.2020.0268. 418 [13] Shirreff G, Zahar J-R, Cauchemez S, Temime L, Opatowski L, EMEA-MESuRS 419 Working Group on the Nosocomial Modelling of SARS-CoV-22. Measuring Basic 420 Reproduction Number to Assess Effects of Nonpharmaceutical Interventions on 421 Nosocomial SARS-CoV-2 Transmission. Emerging Infect Dis 2022;28:1345–54. 422 https://doi.org/10.3201/eid2807.212339. 423 [14] Sanchez-Taltavull D, Castelo-Szekely V, Murugan S, Hamley JID, Rollenske T, 424 Ganal-Vonarburg SC, et al. Regular testing of asymptomatic healthcare workers 425 identifies cost-efficient SARS-CoV-2 preventive measures. PLoS ONE 426 2021;16:e0258700. https://doi.org/10.1371/journal.pone.0258700. 427 Hüttel FB, Iversen A-M, Bo Hansen M, Kjær Ersbøll B, Ellermann-Eriksen S, [15] 428 Lundtorp Olsen N. Analysis of social interactions and risk factors relevant to the 429 spread of infectious diseases at hospitals and nursing homes. PLoS ONE 430 2021;16:e0257684. https://doi.org/10.1371/journal.pone.0257684. 431 [16] Evans S, Stimson J, Pople D, Bhattacharya A, Hope R, White PJ, et al. Quantifying 432 the contribution of pathways of nosocomial acquisition of COVID-19 in English 433 hospitals. Int J Epidemiol 2022;51:393–403. https://doi.org/10.1093/ije/dyab241. 434 [17] Abbas M, Robalo Nunes T, Cori A, Cordey S, Laubscher F, Baggio S, et al. 435 Explosive nosocomial outbreak of SARS-CoV-2 in a rehabilitation clinic: the limits of 436 genomics for outbreak reconstruction. J Hosp Infect 2021;117:124–34. 437 https://doi.org/10.1016/j.jhin.2021.07.013. 438 Lindsey BB, Villabona-Arenas ChJ, Campbell F, Keeley AJ, Parker MD, Shah DR, et [18] 439 al. Characterising within-hospital SARS-CoV-2 transmission events: a retrospective 440 analysis integrating epidemiological and viral genomic data from a UK tertiary care 441 setting across two pandemic waves. MedRxiv 2021. 442 https://doi.org/10.1101/2021.07.15.21260537.

443 [19] Buitrago-Garcia D, Egli-Gany D, Counotte MJ, Hossmann S, Imeri H, Ipekci AM, et 444 al. Occurrence and transmission potential of asymptomatic and presymptomatic 445 SARS-CoV-2 infections: A living systematic review and meta-analysis. PLoS Med 446 2020;17:e1003346. https://doi.org/10.1371/journal.pmed.1003346. 447 [20] Yanes-Lane M, Winters N, Fregonese F, Bastos M, Perlman-Arrow S, Campbell JR, 448 et al. Proportion of asymptomatic infection among COVID-19 positive persons and 449 their transmission potential: A systematic review and meta-analysis. PLoS ONE 450 2020;15:e0241536. https://doi.org/10.1371/journal.pone.0241536. 451 [21] Chin ET, Huynh BQ, Chapman LAC, Murrill M, Basu S, Lo NC. Frequency of 452 Routine Testing for Coronavirus Disease 2019 (COVID-19) in High-risk Healthcare 453 Environments to Reduce Outbreaks. Clin Infect Dis 2021;73:e3127–9. 454 https://doi.org/10.1093/cid/ciaa1383. 455 [22] Huang Q, Mondal A, Jiang X, Horn MA, Fan F, Fu P, et al. SARS-CoV-2 456 transmission and control in a hospital setting: an individual-based modelling study. R 457 Soc Open Sci 2021;8:201895. https://doi.org/10.1098/rsos.201895. 458 [23] Kahn R, Holmdahl I, Reddy S, Jernigan J, Mina MJ, Slayton RB. Mathematical 459 Modeling to Inform Vaccination Strategies and Testing Approaches for Coronavirus 460 Disease 2019 (COVID-19) in Nursing Homes. Clin Infect Dis 2022;74:597–603. 461 https://doi.org/10.1093/cid/ciab517. 462 [24] Litwin T, Timmer J, Berger M, Wahl-Kordon A, Müller MJ, Kreutz C. Preventing 463 COVID-19 outbreaks through surveillance testing in healthcare facilities: a modelling 464 study. BMC Infect Dis 2022;22:105. https://doi.org/10.1186/s12879-022-07075-1. 465 [25] Rosello A, Barnard RC, Smith DRM, Evans S, Grimm F, Davies NG, et al. Impact of 466 non-pharmaceutical interventions on SARS-CoV-2 outbreaks in English care homes: a 467 modelling study. BMC Infect Dis 2022;22:324. https://doi.org/10.1186/s12879-022-468 07268-8. 469 [26] Schmidt AJ, García Y, Pinheiro D, Reichert TA, Nuño M. Using Non-Pharmaceutical 470 Interventions and High Isolation of Asymptomatic Carriers to Contain the Spread of 471 SARS-CoV-2 in Nursing Homes. Life (Basel) 2022;12. 472 https://doi.org/10.3390/life12020180. 473 [27] Smith DRM, Duval A, Pouwels KB, Guillemot D, Fernandes J, Huynh B-T, et al. 474 Optimizing COVID-19 surveillance in long-term care facilities: a modelling study. 475 BMC Med 2020;18:386. https://doi.org/10.1186/s12916-020-01866-6. 476 Vilches TN, Nourbakhsh S, Zhang K, Juden-Kelly L, Cipriano LE, Langley JM, et al. [28] 477 Multifaceted strategies for the control of COVID-19 outbreaks in long-term care 478 facilities in Ontario, Canada. Prev Med 2021;148:106564. 479 https://doi.org/10.1016/j.ypmed.2021.106564. 480 [29] Baek YJ, Lee T, Cho Y, Hyun JH, Kim MH, Sohn Y, et al. A mathematical model of 481 COVID-19 transmission in a tertiary hospital and assessment of the effects of

482 different intervention strategies. PLoS ONE 2020;15:e0241169. 483 https://doi.org/10.1371/journal.pone.0241169. 484 [30] Tsoungui Obama HCJ, Adil Mahmoud Yousif N, Alawam Nemer L, Ngougoue 485 Ngougoue PM, Ngwa GA, Teboh-Ewungkem M, et al. Preventing COVID-19 spread 486 in closed facilities by regular testing of employees-An efficient intervention in long-487 term care facilities and prisons? PLoS ONE 2021;16:e0249588. 488 https://doi.org/10.1371/journal.pone.0249588. 489 [31] Gómez Vázquez JP, García YE, Schmidt AJ, Martínez-López B, Nuño M. Testing 490 and vaccination to reduce the impact of COVID-19 in nursing homes: an agent-based 491 approach. BMC Infect Dis 2022;22:477. https://doi.org/10.1186/s12879-022-07385-4. 492 [32] Holmdahl I, Kahn R, Hay JA, Buckee CO, Mina MJ. Estimation of Transmission of 493 COVID-19 in Simulated Nursing Homes With Frequent Testing and Immunity-Based 494 Staffing. JAMA Netw Open 2021;4:e2110071. 495 https://doi.org/10.1001/jamanetworkopen.2021.10071. 496 [33] Lasser J, Zuber J, Sorger J, Dervic E, Ledebur K, Lindner SD, et al. Agent-based 497 simulations for protecting nursing homes with prevention and vaccination strategies. J 498 R Soc Interface 2021;18:20210608. https://doi.org/10.1098/rsif.2021.0608. 499 [34] Love J, Wimmer MT, Toth DJA, Chandran A, Makhija D, Cooper CK, et al. 500 Comparison of antigen- and RT-PCR-based testing strategies for detection of SARS-501 CoV-2 in two high-exposure settings. PLoS ONE 2021;16:e0253407. 502 https://doi.org/10.1371/journal.pone.0253407. 503 Lucia-Sanz A, Magalie A, Rodriguez-Gonzalez R, Leung C-Y, Weitz JS. Modeling [35] 504 shield immunity to reduce COVID-19 transmission in long-term care facilities. Ann 505 Epidemiol 2023;77:44–52. https://doi.org/10.1016/j.annepidem.2022.10.013. 506 [36] Martos DM, Parcell BJ, Eftimie R. Modelling the transmission of infectious diseases 507 inside hospital bays: implications for COVID-19. Math Biosci Eng 2020;17:8084– 508 104. https://doi.org/10.3934/mbe.2020410. 509 Pham TM, Tahir H, van de Wijgert JHHM, Van der Roest BR, Ellerbroek P, Bonten [37] 510 MJM, et al. Interventions to control nosocomial transmission of SARS-CoV-2: a 511 modelling study. BMC Med 2021;19:211. https://doi.org/10.1186/s12916-021-02060-512 y. 513 [38] See I, Paul P, Slayton RB, Steele MK, Stuckey MJ, Duca L, et al. Modeling 514 Effectiveness of Testing Strategies to Prevent Coronavirus Disease 2019 (COVID-19) 515 in Nursing Homes-United States, 2020. Clin Infect Dis 2021;73:e792-8. 516 https://doi.org/10.1093/cid/ciab110. 517 Smith DRM, Duval A, Zahar JR, EMAE-MESuRS Working Group on Nosocomial [39] 518 SARS-CoV-2 Modelling, Opatowski L, Temime L. Rapid antigen testing as a reactive 519 response to surges in nosocomial SARS-CoV-2 outbreak risk. Nat Commun 520 2022;13:236. https://doi.org/10.1038/s41467-021-27845-w.


521 [40] Zhang Y, Cheng S-R. Evaluating the Need for Routine COVID-19 Testing of 522 Emergency Department Staff: Quantitative Analysis. JMIR Public Health Surveill 523 2020;6:e20260. https://doi.org/10.2196/20260. 524 [41] Ding Y, Agrawal SK, Cao J, Meyers L, Hasenbein JJ. Surveillance Testing for Rapid 525 Detection of Outbreaks in Facilities. ArXiv 2021. 526 https://doi.org/10.48550/arxiv.2110.00170. 527 [42] Yuval J, Nitzan M, Tannenbaum NR, Barak B. Optimizing testing policies for 528 detecting COVID-19 outbreaks. ArXiv 2020. 529 [43] Nguyen LKN, Howick S, McLafferty D, Anderson GH, Pravinkumar SJ, Van Der 530 Meer R, et al. Evaluating intervention strategies in controlling coronavirus disease 531 2019 (COVID-19) spread in care homes: An agent-based model. Infect Control Hosp 532 Epidemiol 2021;42:1060–70. https://doi.org/10.1017/ice.2020.1369. 533 [44] Kendall EA, Arinaminpathy N, Sacks JA, Manabe YC, Dittrich S, Schumacher SG, et 534 al. Antigen-based Rapid Diagnostic Testing or Alternatives for Diagnosis of 535 Symptomatic COVID-19: A Simulation-based Net Benefit Analysis. Epidemiology 536 2021;32:811–9. https://doi.org/10.1097/EDE.000000000001400. 537 [45] Stevenson M, Metry A, Messenger M. Modelling of hypothetical SARS-CoV-2 538 point-of-care tests on admission to hospital from A&E: rapid cost-effectiveness 539 analysis. Health Technol Assess 2021;25:1–68. https://doi.org/10.3310/hta25210. 540 [46] Stevenson M, Metry A, Messenger M. Modelling of hypothetical SARS-CoV-2 point 541 of care tests for routine testing in residential care homes: rapid cost-effectiveness 542 analysis. Health Technol Assess 2021;25:1–74. https://doi.org/10.3310/hta25390. 543 [47] Wilmink G, Summer I, Marsyla D, Sukhu S, Grote J, Zobel G, et al. Real-Time 544 Digital Contact Tracing: Development of a System to Control COVID-19 Outbreaks in Nursing Homes and Long-Term Care Facilities. JMIR Public Health Surveill 545 546 2020;6:e20828. https://doi.org/10.2196/20828. 547 [48] Qiu X, Miller JC, MacFadden DR, Hanage WP. Evaluating the contributions of 548 strategies to prevent SARS-CoV-2 transmission in the healthcare setting: a modelling 549 study. BMJ Open 2021;11:e044644. https://doi.org/10.1136/bmjopen-2020-044644. 550 [49] Jang H, Polgreen PM, Segre AM, Pemmaraju SV. COVID-19 modeling and non-551 pharmaceutical interventions in an outpatient dialysis unit. PLoS Comput Biol 552 2021;17:e1009177. https://doi.org/10.1371/journal.pcbi.1009177. 553 [50] Procter SR, Abbas K, Flasche S, Griffiths U, Hagedorn B, O'Reilly KM, et al. SARS-554 CoV-2 infection risk during delivery of childhood vaccination campaigns: a modelling 555 study. BMC Med 2021;19:198. https://doi.org/10.1186/s12916-021-02072-8. 556 Dy LF, Rabajante JF. A COVID-19 infection risk model for frontline health care [51] 557 workers. Netw Model Anal Health Inform Bioinform 2020;9:57. 558 https://doi.org/10.1007/s13721-020-00258-3.

559 [52] Love J, Keegan LT, Angulo FJ, McLaughlin JM, Shea KM, Swerdlow DL, et al. 560 Continued need for non-pharmaceutical interventions after COVID-19 vaccination in 561 long-term-care facilities. Sci Rep 2021;11:18093. https://doi.org/10.1038/s41598-021-562 97612-w. 563 [53] Nguyen LKN, Megiddo I, Howick S. Hybrid simulation modelling of networks of 564 heterogeneous care homes and the inter-facility spread of Covid-19 by sharing staff. 565 PLoS Comput Biol 2022;18:e1009780. https://doi.org/10.1371/journal.pcbi.1009780. 566 [54] Nguyen LKN, Howick S, McLafferty D, Anderson GH, Pravinkumar SJ, Van Der 567 Meer R, et al. Impact of visitation and cohorting policies to shield residents from 568 covid-19 spread in care homes: an agent-based model. Am J Infect Control 569 2021;49:1105–12. https://doi.org/10.1016/j.ajic.2021.07.001. 570 [55] Oodally A, Hammami P, Reilhac A, Guérineau de Lamérie G, Opatowski L, Temime 571 L. Hospital-level work organization drives the spread of SARS-CoV-2 within 572 hospitals: insights from a multi-ward model. MedRxiv 2021. 573 https://doi.org/10.1101/2021.09.09.21262609. 574 [56] Saurabh S, Kumar R, Kumar N, Bhardwaj P, Nag VL, Garg MK, et al. Dynamics of 575 SARS-CoV-2 Transmission Among Indian Nationals Evacuated From Iran. Disaster 576 Med Public Health Prep 2022;16:627–33. https://doi.org/10.1017/dmp.2020.393. 577 [57] Tofighi M, Asgary A, Merchant AA, Shafiee MA, Najafabadi MM, Nadri N, et al. 578 Modelling COVID-19 transmission in a hemodialysis centre using simulation 579 generated contacts matrices. PLoS ONE 2021;16:e0259970. 580 https://doi.org/10.1371/journal.pone.0259970. 581 [58] Cardinal RN, Meiser-Stedman CE, Christmas DM, Price AC, Denman C, Underwood 582 BR, et al. Simulating a Community Mental Health Service During the COVID-19 583 Pandemic: Effects of Clinician-Clinician Encounters, Clinician-Patient-Family 584 Encounters, Symptom-Triggered Protective Behaviour, and Household Clustering. 585 Front Psychiatry 2021;12:620842. https://doi.org/10.3389/fpsyt.2021.620842. 586 [59] Sánchez-Taltavull D, Castelo-Szekely V, Candinas D, Roldán E, Beldi G. Modelling 587 strategies to organize healthcare workforce during pandemics: Application to COVID-588 19. J Theor Biol 2021;523:110718. https://doi.org/10.1016/j.jtbi.2021.110718. 589 [60] Cheng T, Liu J, Liu Y, Zhang X, Gao X. Measures to prevent nosocomial 590 transmissions of COVID-19 based on interpersonal contact data. Prim Health Care 591 Res Dev 2022;23:e4. https://doi.org/10.1017/S1463423621000852. 592 Kluger DM, Aizenbud Y, Jaffe A, Parisi F, Aizenbud L, Minsky-Fenick E, et al. [61] 593 Impact of healthcare worker shift scheduling on workforce preservation during the COVID-19 pandemic. Infect Control Hosp Epidemiol 2020;41:1443–5. 594 595 https://doi.org/10.1017/ice.2020.337. 596 [62] Jijón S, Al Shafie A, Hassan E, EMAE-MESuRS working group on nosocomial 597 SARS-CoV-2 modeling, Temime L, Jean K, et al. Estimating the risk of incident 598 SARS-CoV-2 infection among healthcare workers in quarantine hospitals: the

599 Egyptian example. Sci Rep 2022;12:19773. https://doi.org/10.1038/s41598-022-600 23428-x. 601 [63] Bosbach WA, Heinrich M, Kolisch R, Heiss C. Maximization of Open Hospital 602 Capacity under Shortage of SARS-CoV-2 Vaccines-An Open Access, Stochastic 603 Simulation Tool. Vaccines (Basel) 2021;9. https://doi.org/10.3390/vaccines9060546. 604 [64] Fosdick BK, Bayham J, Dilliott J, Ebel GD, Ehrhart N. Model-based evaluation of 605 policy impacts and the continued COVID-19 risk at long term care facilities. Infect 606 Dis Model 2022;7:463–72. https://doi.org/10.1016/j.idm.2022.07.003. [65] 607 Holmdahl I, Kahn R, Slifka KJ, Dooling K, Slayton RB. Modeling the impact of 608 vaccination strategies for nursing homes in the context of increased severe acute 609 respiratory syndrome coronavirus 2 community transmission and variants. Clin Infect 610 Dis 2022;75:e880–3. https://doi.org/10.1093/cid/ciac062. 611 Blumberg S, Lu P, Kwan AT, Hoover CM, Lloyd-Smith JO, Sears D, et al. Modeling [66] 612 scenarios for mitigating outbreaks in congregate settings. PLoS Comput Biol 613 2022;18:e1010308. https://doi.org/10.1371/journal.pcbi.1010308. 614 Liu T, Bai Y, Du M, Gao Y, Liu Y. Susceptible-Infected-Removed Mathematical [67] 615 Model under Deep Learning in Hospital Infection Control of Novel Coronavirus 616 Pneumonia. J Healthc Eng 2021;2021:1535046. 617 https://doi.org/10.1155/2021/1535046. 618 [68] Boulware DR, Pullen MF, Bangdiwala AS, Pastick KA, Lofgren SM, Okafor EC, et 619 al. A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for 620 Covid-19. N Engl J Med 2020;383:517–25. https://doi.org/10.1056/NEJMoa2016638. 621 [69] Simonovich VA, Burgos Pratx LD, Scibona P, Beruto MV, Vallone MG, Vázquez C, 622 et al. A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia. N 623 Engl J Med 2021;384:619–29. https://doi.org/10.1056/NEJMoa2031304. 624 [70] Abella BS, Jolkovsky EL, Biney BT, Uspal JE, Hyman MC, Frank I, et al. Efficacy 625 and Safety of Hydroxychloroquine vs Placebo for Pre-exposure SARS-CoV-2 626 Prophylaxis Among Health Care Workers: A Randomized Clinical Trial. JAMA 627 Intern Med 2021;181:195–202. https://doi.org/10.1001/jamainternmed.2020.6319. 628 [71] Abarca K, Iturriaga C, Urzúa M, Le Corre N, Pineda A, Fernández C, et al. Safety 629 and Non-Inferiority Evaluation of Two Immunization Schedules with an Inactivated 630 SARS-CoV-2 Vaccine in Adults: A Randomized Clinical Trial, Vaccines (Basel) 631 2022;10. https://doi.org/10.3390/vaccines10071082. 632 Jafari Y, Yin M, Lim C, Pople D, Evans S, Stimson J, et al. Effectiveness of infection [72] 633 prevention and control interventions, excluding personal protective equipment, to 634 prevent nosocomial transmission of SARS-CoV-2: a systematic review and call for 635 action. Infection Prevention in Practice 2022;4:100192. 636 https://doi.org/10.1016/j.infpip.2021.100192.

637 [73] Chou R, Dana T, Jungbauer R, Weeks C, McDonagh MS. Masks for Prevention of 638 Respiratory Virus Infections, Including SARS-CoV-2, in Health Care and Community 639 Settings □: A Living Rapid Review. Ann Intern Med 2020;173:542–55. 640 https://doi.org/10.7326/M20-3213. 641 [74] Ferris M, Ferris R, Workman C, O'Connor E, Enoch DA, Goldesgeyme E, et al. 642 Efficacy of FFP3 respirators for prevention of SARS-CoV-2 infection in healthcare 643 workers. ELife 2021;10. https://doi.org/10.7554/eLife.71131. 644 [75] Du Z, Liu C, Wang C, Xu L, Xu M, Wang L, et al. Reproduction Numbers of Severe 645 Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants: A Systematic 646 Review and Meta-analysis. Clin Infect Dis 2022;75:e293–5. 647 https://doi.org/10.1093/cid/ciac137. 648 [76] Zhou Y, Ji S. Experimental and numerical study on the transport of droplet aerosols 649 generated by occupants in a fever clinic. Build Environ 2021;187:107402. 650 https://doi.org/10.1016/j.buildenv.2020.107402. 651 [77] Prajapati S, Mehta N, Chharia A, Upadhyay Y. Computational fluid dynamics-based 652 disease transmission modeling of SARS-CoV-2 Intensive Care Unit. Mater Today 653 Proc 2022;56:2967–72. https://doi.org/10.1016/j.matpr.2021.11.013. 654 [78] Saw LH, Leo BF, Nor NSM, Yip CW, Ibrahim N, Hamid HHA, et al. Modeling 655 aerosol transmission of SARS-CoV-2 from human-exhaled particles in a hospital 656 ward. Environ Sci Pollut Res Int 2021;28:53478–92. https://doi.org/10.1007/s11356-021-14519-9. 657 658 Fraser N, Brierley L, Dey G, Polka JK, Pálfy M, Nanni F, et al. The evolving role of [79] 659 preprints in the dissemination of COVID-19 research and their impact on the science 660 communication landscape. PLoS Biol 2021;19:e3000959. 661 https://doi.org/10.1371/journal.pbio.3000959. 662 663 Figure captions: 664 Box 1: Mathematical models of SARS-CoV-2 transmission in health care settings 665 Figure 1: Characteristics of identified models of SARS-CoV-2 transmission within 666 healthcare settings. (A) Cumulative number of modelling studies made accessible per 667 month since March 2020, stratified by primary focus(es) addressed. The date used is the 668 date of first publication, either on a public archive or in a journal. Studies addressing several 669 subjects are counted several times. (B) Geographical distribution of countries on which the 670 modelling is focused. (C) Distribution of modelled healthcare settings per studied country.

- 671 (D) Distribution of addressed subjects, depending on the type of healthcare setting. Studies
- addressing several subjects are counted several times.



Mathematical models are theoretical constructs that mechanistically formalize the dynamic processes underlying SARS-CoV-2 transmission. A typical model splits the individuals present in a healthcare facility into sub-populations, including one or more categories of patients (or residents) and HCWs. Mathematical or statistical tools are used to describe the natural history of infection through the definition of different infection states or "compartments". For instance, in the specific case of SARS-CoV-2, which is characterized by an incubation period subsequent to exposure and the acquisition of (partial) immunity after infection, the main compartments considered are: Susceptible to infection (S), Exposed to infection or incubating (E), Infectious (I), and Recovered or immunized (R). As a large share of infectious individuals may be asymptomatic, the I compartment is often subdivided into asymptomatic (IA) and symptomatic (IS) compartments. Various other sources of heterogeneity may also be considered, including different levels of viral shedding among infectious individuals, or different trajectories of care among symptomatic individuals (e.g., isolation, mechanical ventilation, admission to intensive care, death). Specific contact patterns between individuals of different sub-populations and infection statuses can further be accounted for through the definition of contact matrices.

Compartmental models are most frequent, but agent-based models (also known as individual-based models) are another common formalism, in which each unique individual in the population is explicitly modelled. This enables more detailed integration of heterogeneity in contact patterns, disease progression, transmission risk and other epidemiological processes. Models can further be categorized as either deterministic or stochastic. In deterministic models, there is no randomness in epidemiological processes, and a particular set of initial conditions always results in identical outbreaks. By contrast, in stochastic models, it is possible to account for randomness in the parameters or processes included, resulting in different outbreak trajectories each time the model is run. Stochasticity is particularly relevant in models of healthcare settings, where population sizes are small and randomness can have a strong impact on outbreak dynamics.

Models are used for a variety of purposes. They are widely used to simulate virus transmission in specific settings and populations, allowing for the quantification of virus burden in particular epidemiological scenarios (e.g. after the introduction of a novel SARS-CoV-2 variant into a hospital via newly admitted patients, short-stay visitors, or members of staff infected in the community). Models are also used to enable the *in silico* assessment of public health interventions through the mechanistic implementation of interventions (e.g. testing, isolation, PPE provisioning, contact restrictions, vaccine deployment). Intervention impact can then be evaluated by simulating counterfactual outbreaks with and without the intervention in place. Finally, models are key to analysing reported data from real outbreaks (e.g. time series data, individual line lists of SARS-CoV-2 cases), accounting not only for unobserved processes (e.g., virus transmission) but also incomplete infection data, whether due to the presence of asymptomatic infections, imperfect reporting, or limited surveillance capacity. This allows for the retrospective assessment of true disease burden from a given outbreak (e.g., cumulative infection incidence) as well as estimation of important epidemiological parameters such as R_0 , the basic reproduction number, which describes the average number of secondary cases caused by an index case in an immunologically naïve population. R_0 is particularly helpful to understand the epidemic potential of an emerging pathogen, though its value may vary across distinct sub-populations and settings, such as particular groups of patients and HCWs in particular healthcare facilities.

